Dramatic weight loss with levetiracetam

Epilepsia

Volumn 49, Issue 2, 2008, Pages 308-315

  Gelisse, Philippe ^a,b   Juntas Morales, Raul ^a   Genton, Pierre ^c   Hillaire Buys, Dominique ^d   Diaz, Ophélie ^a   Coubes, Philippe ^a,b   Crespel, Arielle ^a,b  

^a GUI DE CHAULIAC HOSPITAL   (France)

^b INSTITUT DE GÉNOMIQUE FONCTIONNELLE   (France)

^c CENTRE SAINT PAUL   (France)

^d Pharmacovigilance Center of Montpellier   (France)

Author keywords

Epilepsy; Levetiracetam; Weight loss

Indexed keywords

CLONAZEPAM; ETIRACETAM; LAMOTRIGINE; TOPIRAMATE;

ARTICLE; CALORIC INTAKE; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG DOSE REDUCTION; DRUG SAFETY; DRUG WITHDRAWAL; FEEDING BEHAVIOR; FEMALE; FOCAL EPILEPSY; FOOD; HIGH RISK BEHAVIOR; HOSPITALIZATION; HUMAN; MALE; MONOTHERAPY; OBESITY; PRIORITY JOURNAL; SEIZURE; SIDE EFFECT; WEIGHT GAIN; WEIGHT REDUCTION;

ADULT; AGE OF ONSET; ANTICONVULSANTS; BODY MASS INDEX; EPILEPSY; FEEDING BEHAVIOR; FEMALE; HUMANS; MALE; MIDDLE AGED; OBESITY; OVERWEIGHT; PIRACETAM; RISK FACTORS; SEX FACTORS; WEIGHT LOSS;

EID: 38649105825     PISSN: 00139580     EISSN: 15281167     Source Type: Journal    
DOI: 10.1111/j.1528-1167.2007.01273.x     Document Type: Article

References (12)

1. Biton V 2002) Levetiracetam: Adverse experiences. In : Levy RH, Mattson RH, Meldrum BS, Perucca E Eds). Antiepileptic drugs, fifth edition. Lippincott Williams & Wilkins, Philadelphia, pp. 442 47.
2. Briggs DE, French JA 2004) Levetiracetam safety profiles and tolerability in epilepsy patients. Expert Opin Drug Saf 3 : 415 24.
3. Cramer JA, Leppik IE, Rue KD, Edrich P, Kramer G 2003) Tolerability of levetiracetam in elderly patients with CNS disorders. Epilepsy Res 56 : 135 45.
4. Di Bonaventura C, Fattouch J, Mari F, Egeo G, Vaudano AE, Prencipe M, Manfredi M, Giallonardo AT 2005) Clinical experience with levetiracetam in idiopathic generalized epilepsy according to different syndrome subtypes. Epileptic Disord 7 : 231 5.
5. Dinkelacker V, Dietl T, Widman G, Lengler U, Elger CE 2003) Aggressive behavior of epilepsy patients in the course of levetiracetam add-on therapy: report of 33 mild to severe cases. Epilepsy Behav 4 : 537 47.
6. Genton P, Gelisse PH 2002) Valproic Acid: Adverse effects. In : Levy RH, Mattson RH, Meldrum BS, Perucca E (Eds) Antiepileptic drugs, fifth edition. Philadelphia : Lippincott Williams & Wilkins, Philadelphia, pp. 837 51.
7. Genton P, Sadzot B, Fejerman N, Peltola J, Despland PA, Steinhoff B, Rektor I, Wroe S, Maubrey MC, Vandervelden C, van Hammee G, Schlit AF, van Paesschen W 2006) Levetiracetam in a broad population of patients with refractory epilepsy: interim results of the international SKATE trial. Acta Neurol Scand 113 : 387 94.
8. Gidal BE, Sheth RD, Magnus L, Herbeuval AF 2003) Levetiracetam does not alter body weight: analysis of randomized, controlled clinical trials. Epilepsy Res 56 : 121 26.
9. Grunewald R 2005) Levetiracetam in the treatment of idiopathic generalized epilepsies. Epilepsia 46 (Suppl 9 154 60.
10. Hadjikoutis S, Pickersgill TP, Smith PE 2003) Drug points: Weight loss associated with levetiracetam. BMJ 327 : 905.
11. Sachdeo RC, Karia RM 2002) Topiramate: Adverse effects. In : Levy RH, Mattson RH, Meldrum BS, Perucca E Eds). Antiepileptic drugs, 5th ed. Philadelphia : Lippincott Williams & Wilkins, Philadelphia, pp. 760 64.
12. Sheth RD. (2004) Metabolic concerns associated with antiepileptic medications. Neurology 63 (10 Suppl 4 S24 9.